Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901304 | 0.92 | SLC6A9 (1.00) | SLC6A9KCNH2GPR55 | |
| SCHEMBL5201493 | 0.90 | SLC6A9 (0.73) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4908726 | 0.88 | SLC6A9 (0.72) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4906491 | 0.87 | SLC6A9 (0.67) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4909974 | 0.85 | SLC6A9 (0.69) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4908760 | 0.85 | SLC6A9 (0.66) | SLC6A9KCNH2 | |
| SCHEMBL4910937 | 0.83 | SLC6A9 (0.65) | SLC6A9KCNH2GPR55 | |
| SCHEMBL3923127 | 0.82 | SLC6A9 (0.98) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4425015 | 0.82 | SLC6A9 (0.77) | SLC6A9KCNH2GPR55 | |
| SCHEMBL4905318 | 0.82 | SLC6A9 (0.63) | SLC6A9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | claimed |
| EP-1836178-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | claimed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | claimed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| EP-1836178-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | SLC6A9 19/4885KCNH2 2426/4885GPR55 653/4885 |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | SULT1A1, SULT2A1, SULT1E1 | SLC6A9 19/4885KCNH2 2426/4885GPR55 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.